MedPath

Comparison of Pain relieving effect of Etoricoxib with Paracetamol Vs Ibuprofen with Paracetamol after tooth extraction

Completed
Conditions
Pain, unspecified,
Registration Number
CTRI/2020/09/027587
Lead Sponsor
Gajra Raja Medical college
Brief Summary

Analgesic are the drugs which possess significant pain relieving properties by acting in the CNS or on peripheral pain receptors.

Traditional NSAIDS  (i.e. non-selective COX inhibitor such as ibuprofen,diclofenac)have been widely used in outpatient for mild to moderate pain. However, these drugs have well documented adverse effects, such as gastrointestinal intolerability. Furthemore,they need to be administered several times a day.

More effective and practical pain relief regimes,with fewer side-effects,are needed for moderate to severe pain.

Selective COX-2 inhibitors, such as Etoricoxib, Celecoxib have analgesic,anti inflammatory and gastroprotective properties. Etoricoxib has a long half-life(approx-24hrs),Which makes it suitable for once-daily dosing. Due to enhance cardiovascular risk of selective COX-2 inhibitor,some are bannned like Rofecoxib  and Voldecoxib. So,It should be used in lowest dose for the shortest period of time.In Some studies Etoricoxib in lower dose is also found to be efficacious.

Paracetamol is a drug which possess action similar to typical NSAIDS and selective COX-2 inhibitor. It is available in fixed dose combination with both non selective COX and selective COX-2 inhibitor, but exact mechanism of action of Paracetamol is not fully understood but it is suggested to lie predominantly in the CNS(COX-3).It has no effect  on CVS & Gastric irritation is insignificant.

In Some Studies Etoricoxib has also been suggested to be more effective than paracetamol and comparable with ibuprofen. No literature is available regarding the influence of paracetamol when given with etoricoxib on its analgesic efficacy.

Therefore our present study is planned to evaluate the influence of paracetamol when given with low dose of etoricoxib for acute pain relief and compare it with therapeutic dose of etoricoxib also with typical NSAIDS.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
160
Inclusion Criteria
  • 1.Patients who are willing to signed written informed consent.
  • 2.Patients could be of both male and female.
  • 3.All patients who are between 25-60 years of age & weight between 40 kg to 70 kg.
  • 4.Patient who come for tooth extraction in dental OPD.
  • 5.Patient must be medically stable.
  • 6.Patient must have active mobile number.
Exclusion Criteria
  • 1.Patients who are not willing to signed informed consent.
  • 2.Pregnant, breast feeding, child bearing age using contraception.
  • 3.Patient who came for third molar extraction.
  • 4.Patient who are intolerance to Paracetamol, Etoricoxib, Ibuprofen or other NSAIDS.
  • 5.Patient with serious co-morbidity, diabetes, coronary artery disease, cerebrovascular disease, hepatic insufficiency, renal insufficiency, gastric disease, BP instability: pulse <50 or >100, SBP<50 or >180.
  • 6.Patient having other dental problem.
  • 8.Patient on any ongoing medication except antibiotics.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Influence of Paracetamol when given with Etoricoxib 30mg,Etoricoxib 60mg,ibuprofen 400 mg by using VAS (visual analogue scale)At 0 hr,6 hr,24 hr, 48 hr, and 72 hr following intake of study medication.
Secondary Outcome Measures
NameTimeMethod
To assess the safety,cost effectiveness,overall patient experience and compliance between all the groups.After 3 days.

Trial Locations

Locations (1)

G.R.Medical College and J.A. group of Hospital

🇮🇳

Gwalior, MADHYA PRADESH, India

G.R.Medical College and J.A. group of Hospital
🇮🇳Gwalior, MADHYA PRADESH, India
Dr Haresh Bansal
Principal investigator
9131098543
hareshbansal@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.